Skip to main content
NCBI home page
Tobacco Control logoLink to Tobacco Control
. 2003 Sep;12(3):310–316. doi: 10.1136/tc.12.3.310

Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample

S Shiffman 1, J Hughes 1, J Pillitteri 1, S Burton 1
PMCID: PMC1747733  PMID: 12958394

Abstract

Background: In 1996, the US Food and Drug Administration (FDA) approved switching nicotine gum and patch from prescription to over-the-counter (OTC) status. Some expressed concerns that broader availability and lack of physician control might increase persistent use of nicotine replacement therapy (NRT)—that is, use beyond the period specified by the FDA approved label.

Objective: To estimate the incidence of persistent use of OTC nicotine gum and patch for periods of > 3 months, ⩾ 6 months, ⩾ 12 months, and ⩾ 24 months.

Design: Analysis of NRT purchase patterns in data from a population based panel of US households that electronically scanned all household purchases between January 1997 and March 2000.

Subjects: In a national panel of 40 000 US households, 2690 recorded NRT purchases.

Results: Among 805 households that purchased nicotine gum, 2.3% of new purchase incidents led to continuous monthly purchase of gum for ⩾ 6 months. For nicotine patches (2050 households) the percentage was 0.9%. For both gum and patch, the incidence of persistent purchase dropped below 0.4% by 24 months. Allowing one month gaps within a "continuous" purchase run resulted in increased estimates (for gum: 6.7% for ⩾ 6 months and 1.0% for ⩾ 24 months; for patch: 1.7% for ⩾ 6 months and 0.05% for ⩾ 24 months).

Conclusion: Persistent use of nicotine gum and patch is very rare and has not increased with the transition to OTC use, despite removal of physician oversight.

Full Text

The Full Text of this article is available as a PDF (208.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benowitz N. L., Gourlay S. G. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997 Jun;29(7):1422–1431. doi: 10.1016/s0735-1097(97)00079-x. [DOI] [PubMed] [Google Scholar]
  2. Benowitz N. L. Nicotine replacement therapy. What has been accomplished--can we do better? Drugs. 1993 Feb;45(2):157–170. doi: 10.2165/00003495-199345020-00001. [DOI] [PubMed] [Google Scholar]
  3. Benowitz N. L. Pharmacokinetic considerations in understanding nicotine dependence. Ciba Found Symp. 1990;152:186–209. doi: 10.1002/9780470513965.ch11. [DOI] [PubMed] [Google Scholar]
  4. Benowitz N. L., Porchet H., Sheiner L., Jacob P., 3rd Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther. 1988 Jul;44(1):23–28. doi: 10.1038/clpt.1988.107. [DOI] [PubMed] [Google Scholar]
  5. Brass E. P. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med. 2001 Sep 13;345(11):810–816. doi: 10.1056/NEJMra011080. [DOI] [PubMed] [Google Scholar]
  6. Etter J. F., Perneger T. V. Attitudes toward nicotine replacement therapy in smokers and ex-smokers in the general public. Clin Pharmacol Ther. 2001 Mar;69(3):175–183. doi: 10.1067/mcp.2001.113722. [DOI] [PubMed] [Google Scholar]
  7. Fant R. V., Henningfield J. E., Shiffman S., Strahs K. R., Reitberg D. P. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav. 2000 Nov;67(3):479–482. doi: 10.1016/s0091-3057(00)00399-3. [DOI] [PubMed] [Google Scholar]
  8. Garvey A. J., Bliss R. E., Hitchcock J. L., Heinold J. W., Rosner B. Predictors of smoking relapse among self-quitters: a report from the Normative Aging Study. Addict Behav. 1992;17(4):367–377. doi: 10.1016/0306-4603(92)90042-t. [DOI] [PubMed] [Google Scholar]
  9. Hajek P., Jackson P., Belcher M. Long-term use of nicotine chewing gum. Occurrence, determinants, and effect on weight gain. JAMA. 1988 Sep 16;260(11):1593–1596. [PubMed] [Google Scholar]
  10. Henningfield J. E., Keenan R. M. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol. 1993 Oct;61(5):743–750. doi: 10.1037//0022-006x.61.5.743. [DOI] [PubMed] [Google Scholar]
  11. Henningfield J. E. Nicotine medications for smoking cessation. N Engl J Med. 1995 Nov 2;333(18):1196–1203. doi: 10.1056/NEJM199511023331807. [DOI] [PubMed] [Google Scholar]
  12. Hughes J. R., Goldstein M. G., Hurt R. D., Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA. 1999 Jan 6;281(1):72–76. doi: 10.1001/jama.281.1.72. [DOI] [PubMed] [Google Scholar]
  13. Hughes J. R., Gust S. W., Keenan R., Fenwick J. W., Skoog K., Higgins S. T. Long-term use of nicotine vs placebo gum. Arch Intern Med. 1991 Oct;151(10):1993–1998. [PubMed] [Google Scholar]
  14. Hughes J. R., Shiffman S., Callas P., Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control. 2003 Mar;12(1):21–27. doi: 10.1136/tc.12.1.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hughes J. R. Why does smoking so often produce dependence? A somewhat different view. Tob Control. 2001 Mar;10(1):62–64. doi: 10.1136/tc.10.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hurt R. D., Offord K. P., Lauger G. G., Marusić Z., Fagerström K. O., Enright P. L., Scanlon P. D. Cessation of long-term nicotine gum use--a prospective, randomized trial. Addiction. 1995 Mar;90(3):407–413. doi: 10.1046/j.1360-0443.1995.9034079.x. [DOI] [PubMed] [Google Scholar]
  17. Johnson R. E., Hollis J. F., Stevens V. J., Woodson G. T. Patterns of nicotine gum use in a health maintenance organization. DICP. 1991 Jul-Aug;25(7-8):730–735. doi: 10.1177/106002809102500705. [DOI] [PubMed] [Google Scholar]
  18. Joseph A. M., Norman S. M., Ferry L. H., Prochazka A. V., Westman E. C., Steele B. G., Sherman S. E., Cleveland M., Antonuccio D. O., Antonnucio D. O. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996 Dec 12;335(24):1792–1798. doi: 10.1056/NEJM199612123352402. [DOI] [PubMed] [Google Scholar]
  19. Murray R. P., Bailey W. C., Daniels K., Bjornson W. M., Kurnow K., Connett J. E., Nides M. A., Kiley J. P. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. 1996 Feb;109(2):438–445. doi: 10.1378/chest.109.2.438. [DOI] [PubMed] [Google Scholar]
  20. Nemeth-Coslett R., Henningfield J. E., O'Keeffe M. K., Griffiths R. R. Nicotine gum: dose-related effects on cigarette smoking and subjective ratings. Psychopharmacology (Berl) 1987;92(4):424–430. doi: 10.1007/BF00176472. [DOI] [PubMed] [Google Scholar]
  21. Piasecki T. M., Fiore M. C., Baker T. B. Profiles in discouragement: two studies of variability in the time course of smoking withdrawal symptoms. J Abnorm Psychol. 1998 May;107(2):238–251. doi: 10.1037//0021-843x.107.2.238. [DOI] [PubMed] [Google Scholar]
  22. Pierce John P., Gilpin Elizabeth A. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002 Sep 11;288(10):1260–1264. doi: 10.1001/jama.288.10.1260. [DOI] [PubMed] [Google Scholar]
  23. Schauffler H. H., Parkinson M. D. Health insurance coverage for smoking cessation services. Health Educ Q. 1993 Summer;20(2):185–206. doi: 10.1177/109019819302000211. [DOI] [PubMed] [Google Scholar]
  24. Shiffman S., Gitchell J., Pinney J. M., Burton S. L., Kemper K. E., Lara E. A. Public health benefit of over-the-counter nicotine medications. Tob Control. 1997 Winter;6(4):306–310. doi: 10.1136/tc.6.4.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Shiffman S., Paty J. A., Rohay J. M., Di Marino M. E., Gitchell J. The efficacy of computer-tailored smoking cessation material as a supplement to nicotine polacrilex gum therapy. Arch Intern Med. 2000 Jun 12;160(11):1675–1681. doi: 10.1001/archinte.160.11.1675. [DOI] [PubMed] [Google Scholar]
  26. Shiffman Saul, Rolf Clyde N., Hellebusch Stephen J., Gorsline Jane, Gorodetzky Charles W., Chiang Yu-Kun, Schleusener Debra S., Di Marino Michael E. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction. 2002 May;97(5):505–516. doi: 10.1046/j.1360-0443.2002.00141.x. [DOI] [PubMed] [Google Scholar]
  27. West R. J., Russell M. A. Dependence on nicotine chewing gum. JAMA. 1986 Dec 19;256(23):3214–3215. doi: 10.1001/jama.1986.03380230038010. [DOI] [PubMed] [Google Scholar]
  28. West R., Hajek P., Foulds J., Nilsson F., May S., Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) 2000 Apr;149(3):198–202. doi: 10.1007/s002130000382. [DOI] [PubMed] [Google Scholar]
  29. Woods J. H., Katz J. L., Winger G. Abuse liability of benzodiazepines. Pharmacol Rev. 1987 Dec;39(4):251–413. [PubMed] [Google Scholar]

Articles from Tobacco Control are provided here courtesy of BMJ Publishing Group

RESOURCES